Squamous Cell Carcinoma of the Head and Neck: Clinical Trials

15 trials for Squamous Cell Carcinoma of the Head and Neck, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

7 completed, 3 terminated, 2 unknown, 1 active not recruiting. 15 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	15	Completed 7, Terminated 3, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow Squamous Cell Carcinoma of the Head and Neck: new trials by email Literature Review of Squamous Cell Carcinoma of the Head and Neck trials Research Report on Squamous Cell Carcinoma of the Head and Neck

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma De-escalation surgery, Standard Surgery, radiotherapy - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Not yet recruiting	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	356	2026-01-01	2026-01-06
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Terminated	Groupe Oncologie Radiotherapie Tete et Cou	19	2023-12-12	2025-05-09
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN MRG003, Cetuximab injection, Methotrexate Injection - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Recruiting	Lepu Biopharma Co., Ltd.	180	2023-04-04	2026-09-04
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Monalizumab, Cetuximab, Placebo - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Active not recruiting	AstraZeneca	370	2020-10-02	2026-09-09
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT) - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Terminated	EMD Serono Research & Development Institute, Inc.	730	2020-08-07	2025-10-08
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU), placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU) - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Unknown	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	334	2019-06-11	2019-10-30
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Nivolumab, Cetuximab, Cisplatin - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	Bristol-Myers Squibb	74	2017-12-15	2021-08-09
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Avelumab, Chemoradiation - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Terminated	Pfizer	697	2016-11-28	2021-09-22
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer MEDI4736, Tremelimumab, MEDI4736+Tremelimumab - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	AstraZeneca	823	2015-10-15	2021-10-13
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Nivolumab, Cetuximab, Methotrexate - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	Bristol-Myers Squibb	361	2014-05-29	2022-10-05
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Cetuximab, Cisplatin, 5-Fluorouracil - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	Merck KGaA, Darmstadt, Germany	73	2009-12-01	2014-09-03
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin docetaxel - cisplatin - 5-fluorouracil, radiotherapy, cetuximab - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Unknown	Gruppo Oncologico del Nord-Ovest	282	2009-09-01	2017-09-05
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Cetuximab + concomitant boost radiotherapy - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	Merck KGaA, Darmstadt, Germany	70	2009-02-01	2015-07-09
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Erlotinib chlorhydrate, Cisplatin, Radiation therapy - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	Grupo de Investigación Clínica en Oncología Radioterapia	53	2006-01-01	2019-06-06
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Gefitinib, methotrexate - Squamous Cell Carcinoma of the Head and Neck	Phase 3	Completed	AstraZeneca	477	2003-11-01	2011-01-27

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding